Skip to content
2000
Volume 25, Issue 12
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Background

Anlotinib has demonstrated durable clinical benefits in patients with unresectable or metastatic bone and soft-tissue sarcomas.

Methods

92 patients treated with chemotherapy combined with or without anlotinib were collected and analyzed. The objective response rate (ORR) and disease control rate (DCR) were analyzed. Long-term survival was assessed using the Kaplan-Meier method, including median progression-free survival (mPFS) and overall survival (mOS).

Results

Liposarcoma, synovial sarcoma, and rhabdomyosarcoma were the primary pathological subtypes of the 92 patients. The median age was 46 (range, 11-75) years. The ORR and DCR of the anlotinib-chemotherapy combination used as first-line therapy were 31.9% and 85.1%, respectively. However, the ORR and DCR were only 6.7% and 57.8% in the chemotherapy alone, respectively. Compared with the chemotherapy group, improvements were observed in the mPFS and mOS with anlotinib-based regimen (mPFS, 8.3 . 3.0 months; mOS, 59.0 . 22.0 months). Anlotinib-associated adverse events were well tolerated and mainly occurred in grades I and II. New anlotinib-related adverse reactions were not noted.

Conclusion

Anlotinib-based regimen as a first-line therapy showed a positive effect on the treatment of unresectable or metastatic BSTSs. The anlotinib-associated adverse events were minor and well tolerated.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206336884241216070930
2025-01-16
2025-09-05

  • From This Site

    /content/journals/acamc/10.2174/0118715206336884241216070930
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SbaragliaM. BellanE. Dei TosA.P. The 2020 who classification of soft tissue tumours: News and perspectives.Pathologica20201132708410.32074/1591‑951X‑21333179614
     [Google Scholar]
  2. ChiY. FangZ. HongX. YaoY. SunP. WangG. DuF. SunY. WuQ. QuG. WangS. SongJ. YuJ. LuY. ZhuX. NiuX. HeZ. WangJ. YuH. CaiJ. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma.Clin. Cancer Res.201824215233523810.1158/1078‑0432.CCR‑17‑376629895706
     [Google Scholar]
  3. YangZ. ZhengR. ZhangS. ZengH. LiH. ChenW. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China.Cancer Biol. Med.201916356557410.20892/j.issn.2095‑3941.2019.004131565485
     [Google Scholar]
  4. SiegelR.L. MillerK.D. JemalA. Cancer statistics, 2018.CA Cancer J. Clin.201868173010.3322/caac.2144229313949
     [Google Scholar]
  5. WhelanJ.S. DavisL.E. Osteosarcoma, chondrosarcoma, and chordoma.J. Clin. Oncol.201836218819310.1200/JCO.2017.75.174329220289
     [Google Scholar]
  6. RiggiN. SuvàM.L. StamenkovicI. Ewing’s sarcoma. reply.N. Engl. J. Med.2021384151477147833852794
     [Google Scholar]
  7. SinghiE. MooreD. MuslimaniA. Metastatic soft tissue sarcomas: A review of treatment and new pharmacotherapies.P T201843741042930013298
     [Google Scholar]
  8. SmrkeA. WangY. SimmonsC. Update on systemic therapy for advanced soft-tissue sarcoma.Curr. Oncol.20202711Suppl. 1253310.3747/co.27.547532174755
     [Google Scholar]
  9. SavinaM. Le CesneA. BlayJ.Y. Ray-CoquardI. MirO. ToulmondeM. CousinS. TerrierP. Ranchere-VinceD. MeeusP. StoeckleE. HonoréC. SargosP. SunyachM.P. Le PéchouxC. GiraudA. BelleraC. Le LoarerF. ItalianoA. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: The METASARC observational study.BMC Med.20171517810.1186/s12916‑017‑0831‑728391775
     [Google Scholar]
  10. ReedD.R. HayashiM. WagnerL. BinitieO. SteppanD.A. BrohlA.S. ShinoharaE.T. BridgeJ.A. LoebD.M. BorinsteinS.C. IsakoffM.S. Treatment pathway of bone sarcoma in children, adolescents, and young adults.Cancer2017123122206221810.1002/cncr.3058928323337
     [Google Scholar]
  11. JudsonI. VerweijJ. GelderblomH. HartmannJ.T. SchöffskiP. BlayJ.Y. KerstJ.M. SufliarskyJ. WhelanJ. HohenbergerP. Krarup-HansenA. AlcindorT. MarreaudS. LitièreS. HermansC. FisherC. HogendoornP.C.W. dei TosA.P. van der GraafW.T.A. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial.Lancet Oncol.201415441542310.1016/S1470‑2045(14)70063‑424618336
     [Google Scholar]
  12. Yetkin-ArikB. KasteleinA.W. KlaassenI. JansenC.H.J.R. LatulY.P. VittoriM. BiriA. KahramanK. GriffioenA.W. AmantF. LokC.A.R. SchlingemannR.O. van NoordenC.J.F. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.Biochim. Biophys. Acta Rev. Cancer20211875118844610.1016/j.bbcan.2020.18844633058997
     [Google Scholar]
  13. TanH.W. XuY.M. QinS.H. ChenG.F. LauA.T.Y. Epigenetic regulation of angiogenesis in lung cancer.J. Cell. Physiol.202123653194320610.1002/jcp.3010433078404
     [Google Scholar]
  14. LiS. Anlotinib: A novel targeted drug for bone and soft tissue sarcoma.Front. Oncol.20211166485310.3389/fonc.2021.66485334094958
     [Google Scholar]
  15. ZhangL. SunS. WangY. MoY. XiongF. ZhangS. ZengZ. XiongW. LiG. ChenH. GuoC. Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway.Am. J. Cancer Res.202010387088332266096
     [Google Scholar]
  16. JiangX. The role of microenvironment in tumor angiogenesis.J. Exper. Clini. Canc. Res.2020391204
     [Google Scholar]
  17. CampochiaroP.A. AkhlaqA. Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases.Prog. Retin. Eye Res.20218310092110.1016/j.preteyeres.2020.10092133248215
     [Google Scholar]
  18. ShenG. ZhengF. RenD. DuF. DongQ. WangZ. ZhaoF. AhmadR. ZhaoJ. Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development.J. Hematol. Oncol.201811112010.1186/s13045‑018‑0664‑730231931
     [Google Scholar]
  19. BlelochJ.S. BallimR.D. KimaniS. ParkesJ. PanieriE. WillmerT. PrinceS. Managing sarcoma: Where have we come from and where are we going?Ther. Adv. Med. Oncol.201791063765910.1177/175883401772892728974986
     [Google Scholar]
  20. SunY. NiuW. DuF. DuC. LiS. WangJ. LiL. WangF. HaoY. LiC. ChiY. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.J. Hematol. Oncol.20169110510.1186/s13045‑016‑0332‑827716285
     [Google Scholar]
  21. MeyerM. SeetharamM. First-line therapy for metastatic soft tissue sarcoma.Curr. Treat. Options Oncol.2019201610.1007/s11864‑019‑0606‑930675651
     [Google Scholar]
  22. AbrahamsC. WoudbergN.J. LecourS. Anthracycline-induced cardiotoxicity: Targeting high-density lipoproteins to limit the damage?Lipids Health Dis.20222118510.1186/s12944‑022‑01694‑y36050733
     [Google Scholar]
  23. TanR. CongT. XuG. HaoZ. LiaoJ. XieY. LinY. YangX. LiQ. LiuY. XiaY.L. Anthracycline-induced atrial structural and electrical remodeling characterizes early cardiotoxicity and contributes to atrial conductive instability and dysfunction.Antioxid. Redox Signal.2022371-3193910.1089/ars.2021.000235081742
     [Google Scholar]
  24. van der GraafW.T.A. BlayJ.Y. ChawlaS.P. KimD.W. Bui-NguyenB. CasaliP.G. SchöffskiP. AgliettaM. StaddonA.P. BeppuY. Le CesneA. GelderblomH. JudsonI.R. ArakiN. OualiM. MarreaudS. HodgeR. DewjiM.R. CoensC. DemetriG.D. FletcherC.D. Dei TosA.P. HohenbergerP. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial.Lancet201237998291879188610.1016/S0140‑6736(12)60651‑522595799
     [Google Scholar]
  25. MirO. BrodowiczT. ItalianoA. WalletJ. BlayJ.Y. BertucciF. ChevreauC. Piperno-NeumannS. BompasE. SalasS. PerrinC. DelcambreC. Liegl-AtzwangerB. ToulmondeM. DumontS. Ray-CoquardI. ClisantS. TaiebS. GuillemetC. RiosM. CollardO. BozecL. CupissolD. Saada-BouzidE. LemaignanC. EistererW. IsambertN. ChaigneauL. CesneA.L. PenelN. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): A randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Oncol.201617121732174210.1016/S1470‑2045(16)30507‑127751846
     [Google Scholar]
  26. ZhangR.S. LiuJ. DengY.T. WuX. JiangY. The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era.Cancer Med.202211112271228310.1002/cam4.461335191609
     [Google Scholar]
  27. LiuZ. GaoS. ZhuL. WangJ. ZhangP. LiP. ZhangF. YaoW. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.Cancer Med.202110217593760010.1002/cam4.428634564939
     [Google Scholar]
  28. ColosiaA. KhanS. HackshawM.D. OglesbyA. KayeJ.A. SkolnikJ.M. A systematic literature review of adverse events associated with systemic treatments used in advanced soft tissue sarcoma.Sarcoma2016201611310.1155/2016/359760927516726
     [Google Scholar]
  29. LiJ. HanB. LiuH. Outcomes of anlotinib maintenance therapy in patients with advanced NSCLC in a real-world setting.Front. Oncol.20221278586510.3389/fonc.2022.78586535847883
     [Google Scholar]
  30. CaiM. ZhuJ. ZhouG. Efficacy and safety of treating refractory bone and soft tissue sarcoma with anlotinib in different treatment patterns.Comput. Math. Methods Med.2022202211010.1155/2022/328796135991143
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206336884241216070930
Loading
Safety and Efficacy of Anlotinib-based Regimen in Patients with Unresectable or Metastatic Bone and Soft-tissue Sarcomas: A Retrospective Institutional Study
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 25, 851 (2025); https://doi.org/10.2174/0118715206336884241216070930
/content/journals/acamc/10.2174/0118715206336884241216070930
/content/journals/acamc/10.2174/0118715206336884241216070930
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): anlotinib; Bone and soft tissue sarcoma; chondrosarcoma; malignancies; osteosarcoma; tumor

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test